Positive Pregnancy Outcome following First Trimester Dulaglutide Exposure in a Women with Type 2 Diabetes and PCOS: A CaseReport

Authors

  • Bhumi Patel Medical Student, Ohio University Heritage College of Osteopathic Medicine School, USA Author
  • Amber Healy Associate Clinical Professor of Diabetology , Ohio University Heritage College of Osteopathic Medicine, USA Author
  • Amber Healy Diabetes Fellowship Program Director, Ohio Health Physician Group Heritage College, USA Author

DOI:

https://doi.org/10.47363/JDRR/2024(6)178

Keywords:

Type 2 Diabetes, PCOS, GLP-1 Agonists, Pregnancy Outcome, Fetal Development, Fertility, Medication Safety, High-Risk Pregnancy, Maternal Age

Abstract

Background: Insulin has been the gold standard treatment for T2DM during pregnancy. However, emerging studies indicate that GLP-1 agonists have shown significant improvement in insulin resistance. Despite promising results, research conducted on pregnant animal models has shown fetal developmental defects associated with GLP-1 agonists. There is scarcity of research conducted on the use of GLP-1 agonists in human pregnancies. This case report describes the exposure to dulaglutide (GLP-1 agonist) during first trimester of pregnancy.

Case: A 41-year-old female with type 2 diabetes mellitus and polycystic ovarian syndrome had been taking dulaglutide until 15 weeks of gestation. She delivered a healthy baby boy via cesarean delivery at 36 weeks’ gestation.

Conclusion: In our case, exposure to dulaglutide during the first trimester showed no significant developmental effects on the baby. However, current research is insufficient to categorize GLP-1 agonists as safe during pregnancy

Author Biographies

  • Bhumi Patel, Medical Student, Ohio University Heritage College of Osteopathic Medicine School, USA

    Medical Student, Ohio University Heritage College of Osteopathic Medicine School, USA

  • Amber Healy, Associate Clinical Professor of Diabetology , Ohio University Heritage College of Osteopathic Medicine, USA

    Associate Clinical Professor of Diabetology , Ohio University Heritage College of Osteopathic Medicine, USA

  • Amber Healy, Diabetes Fellowship Program Director, Ohio Health Physician Group Heritage College, USA

    Diabetes Fellowship Program Director, Ohio Health Physician Group Heritage College, USA

Downloads

Published

2024-02-29

Issue

Vol. 6 No. 1 (2024): Volume 6 Issue 1

Section

Articles